



Tumor rupture during surgery for gastrointestinal stromal tumors: Pay attention!

Nadia Peparini, Piero Chirletti

Nadia Peparini, Azienda Sanitaria Locale Roma H, 00043 Ciampino, Italy

Piero Chirletti, Department of Surgical Sciences, Sapienza University of Rome, 00161 Rome, Italy

Author contributions: Peparini N conceived and drafted the manuscript, critically revised the manuscript and gave the final approval; Chirletti P critically revised the manuscript and gave its final approval.

Correspondence to: Nadia Peparini, MD, PhD, Azienda Sanitaria Locale Roma H, Via Mario Calò, 5-00043 Ciampino, Italy. nadiapeparini@yahoo.it

Telephone: +39-339-2203940 Fax: +39-76-488423

Received: December 24, 2012 Revised: February 18, 2013

Accepted: March 6, 2013

Published online: March 28, 2013

Abstract

In a recently published letter to the editor, we debated the proposal by Coccolini *et al* to treat gastrointestinal stromal tumors (GISTs) of the esophagogastric junction with enucleation and, if indicated, adjuvant therapy. We highlighted that, because the prognostic impact of a T1 high-mitotic rate esophageal GIST is worse than that of a T1 high-mitotic rate gastric GIST, enucleation may not be adequate surgery for esophagogastric GISTs with a high mitotic rate. In rebuttal, Coccolini *et al* pointed out the possible bias in assessment of the mitotic rates due to the lack of standardized methods and underlined that the site and features of the tumor need to be carefully considered in evaluation of the risk-benefit balance. Here we confirm that, apart from the problematic issue of mitotic counting, enucleation should not be indicated for GISTs at any site to reduce the risk of tumor rupture, which has been recently considered to be an unfavorable prognostic factor, and to avoid microscopic residual tumor.

© 2013 Baishideng. All rights reserved.

Key words: Gastrointestinal stromal tumor; Esophago-

gastric junction; Surgery; Resection; Enucleation

Peparini N, Chirletti P. Tumor rupture during surgery for gastrointestinal stromal tumors: Pay attention! *World J Gastroenterol* 2013; 19(12): 2009-2010 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v19/i12/2009.htm> DOI: <http://dx.doi.org/10.3748/wjg.v19.i12.2009>

TO THE EDITOR

In a recent issue of *World Journal of Gastroenterology*, we debated^[1] the proposal by Coccolini *et al*^[2] to treat gastrointestinal stromal tumors (GISTs) of the esophagogastric junction with enucleation and, if indicated, adjuvant therapy. We highlighted that, because the prognostic impact of a T1 high-mitotic rate esophageal GIST is worse than that of a T1 high-mitotic rate gastric GIST, enucleation may not be adequate surgery for esophagogastric GISTs with a high mitotic rate. In rebuttal, Coccolini *et al*^[3] pointed out the possible bias in the assessment of the mitotic rate due to the lack of standardized methods and underlined that the site and features of the tumor need to be carefully considered in the evaluation of the risk-benefit balance.

Apart from the prognostic differences related to the anatomic localization of the gastric GISTs (gastroesophageal junction-body-distal antrum), problematic mitotic counting is a significant issue in the staging and therapy of GISTs. Controversies exist regarding how large the 50 high-power field areas should be^[4], varying from 5 mm² to 10 mm². The area recommended by the European Guideline represents half of the area recommended by TNM Classification of Malignant Tumors^[5,6].

However, tumor rupture is a highly unfavourable prognostic factor, which should be considered rather than the mitotic rate, tumor site and tumor size in planning an effective treatment for GISTs. According to the modified risk stratification proposed by Joensuu *et al*^[7] and Rutkowski *et al*^[8], patients with tumor rupture are in-

cluded in high-risk category GISTs.

On the other hand, according to updated National Comprehensive Cancer Network Guidelines^[9], Cocolini *et al*^[2] pointed out the value of complete resection, leaving a negative margin and an intact pseudocapsule. GISTs may be soft and fragile because of intratumoral hemorrhage and/or necrosis; anyway they are surrounded by a pseudocapsule that should not be torn during surgery to avoid intra-abdominal seeding. From technical point of view, enucleation of GIST implies that the plane of dissection is conducted along the pseudocapsule with no distance margin on the entire surface of the tumor - *i.e.*, at best microscopic residual tumor (R1) surgery - or rather, enucleation maximizes the risks of R1 and tumor rupture.

We think that complete resection should remain the standard surgical treatment for localized GISTs at any site through wedge resection for small size favorably positioned GISTs and variably extended segmental organ resection depending on the size and site for large and/or unfavourably positioned GISTs. To reduce the risk of tumor rupture with consequent risk of tumor relapse and avoid microscopic residual tumor enucleation should not be indicated for any GISTs. For the risk of tumor rupture, laparoscopic surgery should be avoided with large GISTs^[5].

REFERENCES

- 1 **Peparini N**, Carbotta G, Chirletti P. Enucleation for gastrointestinal stromal tumors at the esophagogastric junction: is this an adequate solution? *World J Gastroenterol* 2011; **17**: 2159-2160 [PMID: 21547139 DOI: 10.3748/wjg.v17.i16.2159]
- 2 **Cocolini F**, Catena F, Ansaloni L, Lazzareschi D, Pinna AD. Esophagogastric junction gastrointestinal stromal tumor: resection vs enucleation. *World J Gastroenterol* 2010; **16**: 4374-4376 [PMID: 20845503 DOI: 10.3748/wjg.v16.i35.4374]
- 3 **Cocolini F**, Catena F, Ansaloni L, Pinna AD. Gastrointestinal stromal tumor and mitosis, pay attention. *World J Gastroenterol* 2012; **18**: 587-588 [PMID: 22363128 DOI: 10.3748/wjg.v18.i6.587]
- 4 **Agaimy A**. Gastrointestinal stromal tumors (GIST) from risk stratification systems to the new TNM proposal: more questions than answers? A review emphasizing the need for a standardized GIST reporting. *Int J Clin Exp Pathol* 2010; **3**: 461-471 [PMID: 20606727]
- 5 **ESMO/European Sarcoma Network Working Group**. Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2012; **23** Suppl 7: vii49-vii55 [PMID: 22997454 DOI: 10.1093/annonc/mds252]
- 6 **Sobin LH**, Gospodarowicz MK, Wittekind Ch. TNM Classification of Malignant Tumors. 7th ed. Wiley-Blackwell, 2010
- 7 **Joensuu H**. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. *Hum Pathol* 2008; **39**: 1411-1419 [PMID: 18774375 DOI: 10.1016/j.humpath.2008.06.025]
- 8 **Rutkowski P**, Bylina E, Wozniak A, Nowecki ZI, Osuch C, Matlok M, Switaj T, Michej W, Wroński M, Gluszek S, Kroc J, Nasierowska-Guttmejer A, Joensuu H. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes. *Eur J Surg Oncol* 2011; **37**: 890-896 [PMID: 21737227 DOI: 10.1016/j.ejso.2011.06.005]
- 9 **Demetri GD**, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, Raut CP, Riedel RF, Schuetze S, Sundar HM, Trent JC, Wayne JD. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. *J Natl Compr Canc Netw* 2010; **8** Suppl 2: S1-41; quiz S42-44 [PMID: 20457867]

P- Reviewers Chen P, Perakath B **S- Editor** Zhai HH
L- Editor Logan S **E- Editor** Li JY

